• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-1MEF filed by MetaVia Inc.

    1/15/26 9:12:56 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTVA alert in real time by email
    S-1MEF 1 tm2528002d20_s1mef.htm FORM S-1MEF

     

    As filed with the Securities and Exchange Commission on January 15, 2026

     

    Registration No. 333-           

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM S-1

     

    REGISTRATION STATEMENT
    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

     

    METAVia INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware 2834 47-2389984
    (State or other jurisdiction of
    incorporation or organization)
    (Primary Standard Industrial
    Classification Code Number)
    (IRS Employer
    Identification Number)

     

    545 Concord Avenue, Suite 210

    Cambridge, Massachusetts 02138

    (857) 702-9600

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

     

     

    Hyung Heon Kim

    President, Chief Executive Officer and Director

    545 Concord Avenue, Suite 210

    Cambridge, Massachusetts 02138

    (857) 702-9600

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    Copies to:

    Phillip D. Torrence, Esq.
    Joshua W. Damm, Esq.
    Honigman LLP
    650 Trade Centre Way, Suite 200
    Kalamazoo, Michigan 49002
    Tel: (269) 337-7700
    Fax: (269) 337-7703
    Michael F. Nertney, Esq.
    Ellenoff Grossman & Schole LLP
    1345 Avenue of the Americas
    11th Floor
    New York, New York 10105
    Telephone: (212) 370-1300

     

    Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement is declared effective.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. x

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. x (File No. 333-292581)

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

      Large accelerated filer ¨ Accelerated filer ¨   
      Non-accelerated filer x  Smaller reporting company x   
          Emerging growth company ¨   

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

    This Registration Statement shall become effective upon filing in accordance with Rule 462(b) under the Securities Act.

     

     

     

     

     

     

    EXPLANATORY NOTE AND INCORPORATION OF

    CERTAIN INFORMATION BY REFERENCE

     

    Pursuant to Rule 462(b) under the Securities Act of 1933, as amended (“Securities Act”), MetaVia Inc. (“Registrant”) is filing this Registration Statement on Form S-1 (this “Registration Statement”) with the Securities and Exchange Commission (“Commission”). This Registration Statement relates to the public offering of securities contemplated by the Registration Statement on Form S-1 (File No. 333-292581) (the “Prior Registration Statement”), which the Registrant originally filed with the Commission on January 5, 2026, as amended on January 12, 2026, and which the Commission declared effective on January 15, 2026.

     

    The Registrant is filing this Registration Statement for the sole purpose of registering up to an aggregate amount of $6,900,000 in (i) Class A Units (the “Class A Units”), with each Class A Unit consisting of (A) one share of our common stock, par value $0.001 per share (the “common stock”), (B) 1.5 Series C warrants to purchase 1.5 shares of common stock (each, a “Series C Common Warrant”), and (C) 1.5 Series D warrants to purchase 1.5 shares of common stock (each, a “Series D Common Warrant” and, together with the Series C Common Warrants, the “Common Warrants”); (ii) Class B Units (the “Class B Units”), with each Class B Unit consisting of (A) one pre-funded warrant (each, a “pre-funded warrant”) to purchase one share of common stock, in lieu of shares of common stock, (B) 1.5 Series C Common Warrants, and (C) 1.5 Series D Common Warrants; and (iii) shares of our common stock issuable upon exercise of pre-funded warrants and Common Warrants. The additional securities that are being registered for sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in the Calculation of Registration Fee Table (Exhibit 107) contained in the Prior Registration Statement. The information set forth in the Prior Registration Statement and all exhibits to the Prior Registration Statement are incorporated by reference into this Registration Statement.

     

    The required opinions and consents are listed on the Exhibit Index attached hereto and filed herewith.

     

    EXHIBIT INDEX

     

    Exhibit
    Number
      Description
       
    5.1   Opinion of Honigman LLP.
       
    23.1   Consent of Independent Registered Public Accounting Firm (BDO USA, P.C.).
       
    23.2   Consent of Honigman LLP (included in Exhibit 5.1).
       
    24.1   Power of Attorney (incorporated by reference to Exhibit 24.1 to the Registration Statement on Form S-1 (Registration No. 333-292581)).
       
    107   Filing Fee Table.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on the 15th day of January, 2026.

     

      MetaVia Inc.
         
      By: /s/ Hyung Heon Kim
        Hyung Heon Kim
        President, Chief Executive Officer and Director

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

     

    Signature   Title   Date

     

    /s/ Hyung Heon Kim   President, Chief Executive Officer and   January 15, 2026
    Hyung Heon Kim   Director (Principal Executive Officer)    
             
    /s/ Marshall H. Woodworth   Chief Financial Officer   January 15, 2026
    Marshall H. Woodworth   (Principal Financial Officer and Principal
    Accounting Officer)
       

     

    *        
    Andrew I. Koven   Chairman of the Board   January 15, 2026
             
    *        
    Mark A. Glickman   Director   January 15, 2026
             
    *        
    Jason L. Groves   Director   January 15, 2026
             
    *        
    Michael Salsbury   Director   January 15, 2026
             
    *        
    D. Gordon Strickland   Director   January 15, 2026
             
    *        
    James P. Tursi, M.D.   Director   January 15, 2026

     

    *By:    /s/ Hyung Heon Kim  
      Hyung Heon Kim  
      Attorney-in-Fact  

     

    January 15, 2026

     

     

     

    Get the next $MTVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTVA

    DatePrice TargetRatingAnalyst
    9/4/2025$12.00Buy
    H.C. Wainwright
    12/30/2024$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $MTVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Woodworth Marshall H was granted 28,000 shares, increasing direct ownership by 1,024% to 30,734 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    1/27/26 4:02:10 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & President Kim Hyung Heon was granted 32,000 shares, increasing direct ownership by 577% to 37,545 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    1/27/26 4:01:16 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Woodworth Marshall H gifted 14,200 shares, decreasing direct ownership by 32% to 30,079 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    8/13/25 4:36:41 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

    16-Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy AdultsCAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that the Institutional Review Board (IRB) at Clinical Pharmacology of Miami has approved the Company's Phase 1 Part 3 clinical trial of its lead asset, DA-1726, a novel, dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors. The approval enables initiation of Part 3 of the Phase 1 program, which consists of two 16-week titration cohorts evaluating on

    3/18/26 8:00:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

    NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,

    3/13/26 8:35:00 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035

    Patent Portfolio Includes 48 Granted and Pending Patents in the U.S., Europe, Japan, China and other Countries, Providing Protection Into 2035, Unless Extended FurtherCAMBRIDGE, Mass., March 12, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a comprehensive global intellectual property portfolio supporting vanoglipel (DA-1241), its novel, orally available G-protein-coupled receptor 119 (GPR119) agonist. This currently includes 48 granted and pending patents across three patent families in the U.S., Europe, Japan, China and other countries, providing protection into 2035, unless extended

    3/12/26 9:01:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    SEC Filings

    View All

    MetaVia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - MetaVia Inc. (0001638287) (Filer)

    3/18/26 8:05:20 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia Inc. filed SEC Form 8-K: Leadership Update

    8-K - MetaVia Inc. (0001638287) (Filer)

    1/27/26 4:01:21 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - MetaVia Inc. (0001638287) (Filer)

    1/16/26 4:05:21 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on MetaVia with a new price target

    H.C. Wainwright resumed coverage of MetaVia with a rating of Buy and set a new price target of $12.00

    9/4/25 9:02:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on MetaVia with a new price target

    H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00

    12/30/24 7:25:48 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Woodworth Marshall H bought $9,940 worth of shares (14,200 units at $0.70), increasing direct ownership by 47% to 44,279 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    6/4/25 4:01:12 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Dong-A St Co., Ltd bought $3,300,000 worth of shares (4,647,887 units at $0.71), increasing direct ownership by 87% to 9,995,679 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    5/20/25 4:16:39 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Leadership Updates

    Live Leadership Updates

    View All

    MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

    CAMBRIDGE, Mass., March 4, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Thursday, March 12, 2026 at 10:30 am ET. This will be a live, interactive online event where investors are invited to ask the company questions

    3/4/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care